cerecor-logo-final.png
Cerecor Announces Appointment of H. Jeffery Wilkins MD as Chief Development Officer
March 06, 2020 09:00 ET | Cerecor Inc.
ROCKVILLE, Md., March 06, 2020 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
cerecor-logo-final.png
Cerecor and Aevi Genomic Medicine Complete Merger
February 03, 2020 16:15 ET | Cerecor Inc.
-Cerecor Emerges as a Leading Biopharmaceutical Company in Rare Pediatric and Orphan Diseases -Mike Cola Named Chief Executive Officer and Dr. Garry Neil Named Chief Medical Officer ROCKVILLE, Md.,...
cerecor-logo-final.png
Cerecor to Acquire Aevi Genomic Medicine
December 05, 2019 08:45 ET | Cerecor Inc.
-Expands Clinical-stage Pipeline, Further Positioning Cerecor as a Leader in Rare and Orphan Diseases-Enhances Leadership Team with the Addition of Chief Executive Officer and Chief Medical...
cerecor-logo-final.png
Cerecor Reports Third Quarter 2019 Results
November 14, 2019 06:30 ET | Cerecor Inc.
Sale of Pediatric Portfolio in a Deal Valued in Excess of $43 MillionFirst Patient Enrolled in Diabetic OH Trial with CERC-301Completed Phase 1 Healthy Volunteer Study with CERC-802CERC-802 IND...
cerecor-logo-final.png
Cerecor Announces Clinical Updates on CERC-301 and CERC-802
November 11, 2019 06:30 ET | Cerecor Inc.
- CERC-301 Enrolls First Patient in Diabetic Orthostatic Hypotension Trial -CERC-802 Completes Phase I Safety Study in Healthy Volunteers ROCKVILLE, Md., Nov. 11, 2019 (GLOBE NEWSWIRE) --...
cerecor-logo-final.png
Cerecor Closes Deal to Sell Pediatric Portfolio
November 04, 2019 06:30 ET | Cerecor Inc.
ROCKVILLE, Md., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for orphan...
cerecor-logo-final.png
Cerecor To Sell Pediatric Portfolio to AYTU BioScience
October 14, 2019 06:30 ET | Cerecor Inc.
-Deal Valued in Excess of $32 Million-Eliminates Debt Associated with Avadel / Deerfield Agreement-Provides Non-Dilutive Cash Generation to Fund R&D  -Extends Runway Towards NDA Submission of...
cerecor-logo-final.png
Cerecor Receives Fast Track Designation from FDA for CERC-802 for the Treatment of Mannose-Phosphate Isomerase Deficiency
August 21, 2019 06:30 ET | Cerecor Inc.
ROCKVILLE, Md., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...
cerecor-logo-final.png
Cerecor Reports Second Quarter 2019 Results
August 08, 2019 16:05 ET | Cerecor Inc.
-Positive Final Results with CERC-301 in nOH-First Patient Enrolled in CDG FIRST Trial- FDA Acceptance of IND Application of CERC-802 ROCKVILLE, Md., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc....
cerecor-logo-final.png
FDA Accepts IND Application for Cerecor’s Investigational Drug CERC-802 for the treatment of MPI-CDG
July 29, 2019 06:30 ET | Cerecor Inc.
ROCKVILLE, Md., July 29, 2019 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare...